Michelle M. Estrella

Michelle M. Estrella

Auto-generated profile, based on publicly available information

Michelle M. Estrella

Renal Section, San Francisco VA Health Care System, Kidney Health Research Collaborative, University of California San Francisco, San Francisco, California

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 August 2022 in Kidney360
Verified
Journal Article
Closed access
PDF file
DCDebbie C. Chen
Debbie C. Chen
OPO. Alison Potok
O. Alison Potok
DRDena E. Rifkin
Dena E. Rifkin
MEMichelle M. Estrella
Michelle M. Estrella
Cystatin C has been shown to be a reliable and accurate marker of kidney function across diverse populations. The 2012 Kidney Disease Improving Global Outcomes (KDIGO) guidelines recommended using cystatin C to confirm the diagnosis of chronic kidney disease (CKD) determined by creatinine-based estimated glomerular filtration rate (eGFR) and to estimate kidney function when accurate eGFR estimates are needed for clinical decision-making. In the efforts to remove race from eGFR calculations in the United States, the National Kidney Foundation (NKF) and American Society of Nephrology (ASN) Joint Task Force recommended increasing availability and clinical adoption of cystatin C to assess kidney function. This review summarizes the key advantages and limitations of cystatin C use in clinical practice. Our goals were to review and discuss the literature on cystatin C; understand the evidence behind the recommendations for its use as a marker of kidney function to diagnose CKD and risk stratify patients for adverse outcomes; discuss the challenges of its use in clinical practice; and guide clinicians on its interpretation.

17 February 2022 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
DCDebbie C. Chen
Debbie C. Chen
MSMichael G. Shlipak
Michael G. Shlipak
RSRebecca Scherzer
Rebecca Scherzer
SBScott R. Bauer
Scott R. Bauer
OPO. Alison Potok
O. Alison Potok
MEMichelle M. Estrella
Michelle M. Estrella
The burden of chronic kidney disease (CKD) in the US is substantial, with more than 130 000 persons progressing to end-stage kidney disease (ESKD) each year.1 Estimated glomerular filtration rate (eGFR) is crucial for staging and risk-stratifying persons with CKD, as lower eGFR has an independent, graded association with higher risk for ESKD and mortality.2-4 Creatinine and cystatin C are biomarkers used to determine eGFR. However, cystatin C–based eGFR (eGFRcys) and creatinine-based eGFR (eGFRcr) measured in the same individual may be highly discrepant.5,6 Currently, there is no guidance for CKD risk stratification when eGFRcys and eGFRcr are substantially different, and the clinical implications of these differences are unclear.

9 July 2022 in American Journal of Kidney Diseases
Verified
Journal Article
Closed access
DCDebbie C. Chen
Debbie C. Chen
MSMichael G. Shlipak
Michael G. Shlipak
RSRebecca Scherzer
Rebecca Scherzer
NBNisha Bansal
Nisha Bansal
OPO. Alison Potok
O. Alison Potok
MEMichelle M. Estrella
Michelle M. Estrella

5 October 2023 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
LILesley A. Inker
Lesley A. Inker
HTHocine Tighiouart
Hocine Tighiouart
OAOgechi M. Adingwupu
Ogechi M. Adingwupu
MSMichael G. Shlipak
Michael G. Shlipak
ADAlessandro Doria
Alessandro Doria
ALAndrew S. Levey
Andrew S. Levey
Significance Statement: New eGFR equations from Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) and European Kidney Function Consortium (EKFC) using creatinine (eGFRcr), cystatin C (eGFRcys), and both (eGFRcr-cys) have sufficient accuracy for use in clinical practice, leading to uncertainty in selecting equations for implementation. The authors evaluated performance of equations in an independent population of 4050 adults and evaluated other considerations important for implementation. They found that CKD-EPI and EKFC equations are approaching convergence, with better performance of eGFRcr-cys equations in the overall group and fewer differences among race, sex, and age subgroups than eGFRcr equations. Larger differences among eGFRcr equations reflect regional population differences in creatinine, forcing a trade-off between accuracy and uniformity in global implementation of eGFRcr equations. More widespread use of cystatin C could avoid this trade-off. Background: New CKD-EPI and EKFC eGFR equations using eGFRcr, eGFRcys, and both (eGFRcr-cys) have sufficient accuracy for use in clinical practice. A better understanding of the equations, including their performance in race, sex and age subgroups, is important for selection of eGFR equations for global implementation. Methods: We evaluated performance (bias and P 30 ) of equations and methods used for equation development in an independent study population comprising 4050 adults pooled from 12 studies. The mean (SD) measured GFR was 76.4 (29.6) ml/min per 1.73 m 2 and age 57.0 (17.4) years, with 1557 (38%) women and 579 (14%) Black participants. Results: Coefficients for creatinine, cystatin C, age, and sex in the CKD-EPI and EKFC equations are similar. Performance of the eGFRcr-cys equations in the overall population (bias <±5 ml/min per 1.73 m 2 and P 30 >90%) was better than the eGFRcr or eGFRcys equations, with fewer differences among race, sex, and age subgroups. Differences in performance across subgroups reflected differences in diversity of source populations and use of variables for race and sex for equation development. Larger differences among eGFRcr equations reflected regional population differences in non-GFR determinants of creatinine. Conclusion: CKD-EPI and EKFC equations are approaching convergence. It is not possible to maximize both accuracy and uniformity in selecting one of the currently available eGFRcr equations for implementation across regions. Decisions should consider methods for equation development in addition to performance. Wider use of cystatin C with creatinine could maximize both accuracy and uniformity of GFR estimation using currently available equations.

1 August 2019 in Kidney International
Verified
Journal Article
Closed access
ABAlexander L. Bullen
Alexander L. Bullen
RKRonit Katz
Ronit Katz
ALAlexandra K. Lee
Alexandra K. Lee
CACheryl A.M. Anderson
Cheryl A.M. Anderson
ACAlfred K. Cheung
Alfred K. Cheung
MEMichelle M. Estrella
Michelle M. Estrella

1 May 2024 in Circulation: Heart Failure
Verified
Journal Article
Closed access
PDF file
NBNisha Bansal
Nisha Bansal
LZLeila R. Zelnick
Leila R. Zelnick
RSRebecca Scherzer
Rebecca Scherzer
MEMichelle Estrella
Michelle Estrella
MSMichael G. Shlipak
Michael G. Shlipak
BACKGROUND: Heart failure (HF) is associated with poor outcomes in people with chronic kidney disease, yet it is unknown whether outcomes differ by HF subtype. This study aimed to examine associations of incident HF with preserved ejection fraction (HFpEF) versus HF with reduced ejection fraction (HFrEF) with progression to end-stage kidney disease (ESKD) and mortality. METHODS: We studied individuals with chronic kidney disease in the CRIC study (Chronic Renal Insufficiency Cohort) who were free of HF at cohort entry. Incident HF hospitalizations were adjudicated and classified into HFpEF (ejection fraction, ≥50%) or HFrEF (ejection fraction, <50%) based on echocardiograms performed during the hospitalization or at a research study visit. ESKD was defined as need for chronic dialysis or kidney transplant. Cox proportional hazards were used to evaluate the association of time-updated HF subtype with risk of ESKD and mortality, adjusting for demographics, comorbidities, and medication use. RESULTS: Among the 3557 study participants without HF at cohort entry, mean age was 57 years and mean estimated glomerular filtration rate was 45 mL/min per 1.73 m 2 . A total of 682 participants had incident HF. Incidence rates for HFpEF and HFrEF were 0.9 (95% CI, 0.8–1.0) and 0.7 (95% CI, 0.6–0.8) per 100 person-years, respectively ( P difference =0.005). Associations of incident HF with progression to ESKD were not statistically different for HFpEF (hazard ratio, 2.06 [95% CI, 1.66–2.56]) and HFrEF (hazard ratio, 1.80 [95% CI, 1.36–2.38]; P =0.42). The associations with mortality were stronger for HFrEF (hazard ratio, 2.73 [95% CI, 2.24–3.33]) compared with HFpEF (hazard ratio, 1.99 [95% CI, 1.65–2.40]; P =0.0002). CONCLUSIONS: In a chronic kidney disease population, the rates of HFpEF hospitalizations were greater than that of HFrEF. Risk of ESKD was high but not statically different across HF subtypes. There was a stronger association of HFrEF with mortality. Prevention and treatment of both HFpEF and HFrEF should be central priorities to improve outcomes in chronic kidney disease.